Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy and Ruxolitinib for GVHD Prophylaxis in Myelofibrosis
NCT02806375Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by First Saint Petersburg State Medical University. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02806375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806375.